PaxMedica, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PXMD research report →
Price Chart
About the company
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms.
- CEO
- Howard J. Weisman
- IPO
- 2022
- Employees
- 6
- HQ
- Tarrytown, NY, US
Get TickerSpark's AI analysis on PXMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $88.39K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.29
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1046.98%
- ROIC
- -415.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-16,145,000
- Net Income
- $-18,290,000-23.6%
- EPS
- $-11.00+61.7%
- OCF Growth
- -77.4%
- FCF Growth
- -77.4%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.51
- RSI (14)
- 61
- Avg Volume
- 1.39K
No earnings-call transcripts are available for PXMD yet.
- Free Float
- 8.5%
- Shares Outstanding
- 126.26M
- Float Shares
- 10.69M
of shares held by institutions
8 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 24 | Weisman Howard J. | other | 2,927 |
| Mar 12, 24 | Sheldon Stephen | other | 3,356 |
| Mar 12, 24 | Rome Zachary | other | 4,904 |
| Mar 12, 24 | LaRochelle Karen | other | 604 |
| Mar 12, 24 | Hough David W. | other | 1,452 |
| Mar 12, 24 | Coelho John F | other | 207 |
| Mar 12, 24 | CASAMENTO CHARLES J | other | 992 |
| Feb 21, 24 | Hough David W. | other | 291 |
| Feb 21, 24 | Sheldon Stephen | other | 243 |
| Jan 29, 24 | Rome Zachary | sell | 811 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PXMD coverage
Recent articles, reports, and earnings notes.
No research on PXMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PXMD report →ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast
defenseworld.net · Mar 3
Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX)
defenseworld.net · Dec 18
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
accesswire.com · Jan 14
PaxMedica Secures Immediate Exercise of Warrants
accesswire.com · Sep 3
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
accesswire.com · Aug 27
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
globenewswire.com · May 15
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
globenewswire.com · Apr 23
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
globenewswire.com · Apr 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.